Nanobiotix S.A. to Post FY2025 Earnings of $1.07 Per Share, Leerink Partnrs Forecasts (NASDAQ:NBTX)

Nanobiotix S.A. (NASDAQ:NBTX) – Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Nanobiotix in a research note issued on Thursday, April 25th. Leerink Partnrs analyst J. Chang now expects that the company will earn $1.07 per share for the year, up from their previous estimate of $1.06. The consensus estimate for Nanobiotix’s current full-year earnings is ($0.86) per share.

Nanobiotix Stock Down 2.9 %

Shares of NBTX stock opened at $5.74 on Monday. The stock has a 50-day simple moving average of $6.29 and a 200 day simple moving average of $6.55. Nanobiotix has a fifty-two week low of $1.75 and a fifty-two week high of $11.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nanobiotix stock. Johnson & Johnson bought a new stake in shares of Nanobiotix S.A. (NASDAQ:NBTX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 959,637 shares of the company’s stock, valued at approximately $8,397,000. Nanobiotix makes up 3.1% of Johnson & Johnson’s holdings, making the stock its 9th biggest position. Johnson & Johnson owned 2.65% of Nanobiotix at the end of the most recent quarter. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.